Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | HTR2B | P41595 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4792242 | 0.85 | HRH3 (0.48) | HRH3DRD2DRD3 | |
| SCHEMBL4790927 | 0.84 | HRH3 (0.47) | HTR2CHRH3DRD2HTR2AHRH1 | |
| SCHEMBL5098547 | 0.80 | HTR2C (0.58) | HTR2CHTR2BHRH3KDM4EALDH1A1 | |
| SCHEMBL4770231 | 0.77 | HTR2C (0.60) | HTR2CHTR2BKMT2AKDM4EALDH1A1 | |
| SCHEMBL4771909 | 0.75 | HRH3 (0.55) | HRH3DRD2HRH1DRD3 | |
| SCHEMBL16715429 | 0.73 | HTR2C (0.55) | HTR2CHTR2BKMT2ADRD2DRD4 | |
| SCHEMBL1958497 | 0.71 | DRD2 (0.44) | HTR2CHTR2BKMT2AHRH3DRD2 | |
| Hydrochloric Acid SCHEMBL1957323 | 0.71 | HTR2C (0.61) | HTR2CHTR2BKMT2ADRD2HTR1A | |
| SCHEMBL2625803 | 0.71 | HTR2C (0.51) | HTR2CHTR2BKMT2AHRH3DRD2 | |
| SCHEMBL4773205 | 0.70 | HTR2C (1.00) | HTR2CHTR2BADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429579-B2 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM, PLC (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1335915-B1 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2008-01-02 | — | — | EP | disclosed |
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | SMITHKLINE BEECHAM PLC (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1335915-A2 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002040471-A2 | TETRAHYDROBENZAZEPINE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171606-A1 | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | DRD3, DRD2, DRD1 | HTR2C 52/4885HTR2B 85/4885KMT2A 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.